JP2009506080A5 - - Google Patents

Download PDF

Info

Publication number
JP2009506080A5
JP2009506080A5 JP2008528306A JP2008528306A JP2009506080A5 JP 2009506080 A5 JP2009506080 A5 JP 2009506080A5 JP 2008528306 A JP2008528306 A JP 2008528306A JP 2008528306 A JP2008528306 A JP 2008528306A JP 2009506080 A5 JP2009506080 A5 JP 2009506080A5
Authority
JP
Japan
Prior art keywords
effective amount
therapeutic effect
receptor agonist
opioid receptor
antagonize
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008528306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506080A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2006/001441 external-priority patent/WO2007025383A1/en
Publication of JP2009506080A publication Critical patent/JP2009506080A/ja
Publication of JP2009506080A5 publication Critical patent/JP2009506080A5/ja
Pending legal-status Critical Current

Links

JP2008528306A 2005-08-30 2006-08-30 超低用量のα−２−受容体アンタゴニストを用いる、オピオイド受容体アゴニストの治療作用の増強方法および／またはオピオイド受容体アゴニストに対する耐性の阻害方法もしくは逆転方法 Pending JP2009506080A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71254505P 2005-08-30 2005-08-30
US75395805P 2005-12-23 2005-12-23
PCT/CA2006/001441 WO2007025383A1 (en) 2005-08-30 2006-08-30 Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist

Publications (2)

Publication Number Publication Date
JP2009506080A JP2009506080A (ja) 2009-02-12
JP2009506080A5 true JP2009506080A5 (https=) 2009-10-22

Family

ID=37808435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008528306A Pending JP2009506080A (ja) 2005-08-30 2006-08-30 超低用量のα−２−受容体アンタゴニストを用いる、オピオイド受容体アゴニストの治療作用の増強方法および／またはオピオイド受容体アゴニストに対する耐性の阻害方法もしくは逆転方法

Country Status (7)

Country Link
US (1) US20070060501A1 (https=)
EP (1) EP1942903A4 (https=)
JP (1) JP2009506080A (https=)
AU (1) AU2006287070A1 (https=)
CA (1) CA2627158A1 (https=)
IL (1) IL189869A0 (https=)
WO (1) WO2007025383A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
WO2007057508A2 (en) * 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
CA2657481A1 (en) * 2006-07-21 2008-01-24 Queen's University At Kingston Methods and therapies for potentiating a therapeutic action of an alpha- 2 adrenergic receptor agonist and inhibiting and/or reversing tolerance to alpha- 2 adrenergic receptor agonists
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
PL2137191T3 (pl) * 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
JP2010522756A (ja) * 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
EP2565195B1 (en) * 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US20110053913A1 (en) * 2009-06-25 2011-03-03 Khem Jhamandas Methods and Therapies for Alleviating Pain
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20170216277A1 (en) * 2016-01-06 2017-08-03 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
EP3833346A4 (en) * 2018-08-08 2022-08-03 Torralva Medical Therapeutics LLC Compositions for opiate and opioid prevention and reversal, and methods of their use
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI81092C (fi) * 1986-05-15 1990-09-10 Farmos Oy Foerfarande foer framstaellning av terapeutiskt aktiva 4(5)-(2,3-dihydro-1h-inden-2-yl)-imidazolderivat.
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
DE19758564A1 (de) * 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
EP1326642A2 (en) * 2000-09-29 2003-07-16 Board of Trustees operating Michigan State University Catecholamine pharmaceutical compositions and methods
WO2003082275A1 (en) * 2002-03-29 2003-10-09 Orion Corporation Treatment of dependence and dependence related withdrawal symptoms

Similar Documents

Publication Publication Date Title
JP2009506080A5 (https=)
FR25C1012I1 (fr) Posologie d'un agoniste du récepteur s1p
NO2020027I1 (no) glasdegib, eventuelt i form av et farmasøytisk akseptabelt salt, inkludert maleatsaltet
EP2120575A4 (en) AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS
IL202752A0 (en) Il-23 receptor antagonists and uses thereof
BRPI0821683A2 (pt) Medicamento compreendendo um agonista parassimpatético e um antagonista simpatético ou agonista simpatético
PL2468290T3 (pl) Antagoniści aktywiny-ActRII do stosowania w leczeniu niedokrwistości
PL2054411T3 (pl) Nowe związki, ich izomery lub ich farmaceutycznie dopuszczalne sole jako antagoniści receptora waniloidowego oraz zawierające je kompozycje farmaceutyczne
IL189869A0 (en) Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptor agonists using an ultralow dose of an alpha-2 receptor antagonist
IL199680A0 (en) Piperidine gpcr agonists, compositions comprising the same, processes for producing ths same and uses thereof
EP2049110A4 (en) BRAZED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
MX2009009201A (es) Composicion farmaceutica.
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
EP2137191B8 (en) Peripheral opioid receptor antagonists and uses thereof
PL2238110T3 (pl) Pochodne 5,6-bisarylo-2-pirydyno-karboksamidu, ich wytwarzanie i ich zastosowanie terapeutyczne jako antagonistów receptora Urotensyny II
CL2013001943A1 (es) Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma.
HRP20150661T1 (en) Peripheral opioid receptor and antagonists and uses thereof
EP2170064A4 (en) 6,5-pyrrolopiperidine tachykinin receptor antagonists
IL198780A0 (en) Pharmaceutical formulation comprising neurokinin antagonist
DK2121630T3 (da) Hurtigt dissocierende dopamin-2-receptor-antagonister
DE602005004011D1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
CL2007002611A1 (es) Compuestos derivados de eter diarilico, antagonistas de los receptores opioides mu, kappa y delta; composicion farmaceutica; y uso para el tratamiento de la obesidad.
PL2091938T3 (pl) Piperydynyloaminipirazyny i ich zastosowanie jako szybko dysocjujących antagonistów receptora dopaminy 2
WO2007115975A3 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen